Table 2.
Use of splenectomy (diagnostic or other) and chemotherapy after a diagnostic splenectomy, among patients with primary splenic lymphomas.
| SMZL | FL | DLBCL | MCL | T-cell | Other | All | |
|---|---|---|---|---|---|---|---|
| Treatment modalities, % a | |||||||
| Splenectomy alone | 38.5 | 50.2 | 19.1 | 24.9 | 22.4 | 38.9 | 32.6 |
| Splenectomy and chemotherapy | 10.4 | 27.1 | 50.8 | 29.9 | 36.1 | 20.8 | 25.3 |
| Chemotherapy alone | 32.1 | 13.1 | 25.3 | 33.0 | 33.5 | 28.8 | 29.0 |
| No treatment | 19.0 | 9.7 | 4.8 | 12.3 | 8.0 | 11.4 | 13.1 |
| Any splenectomy, % | 48.9 | 77.3 | 69.9 | 54.8 | 58.6 | 59.7 | 57.9 |
| Diagnostic splenectomy, % b | 43.1 | 67.3 | 67.5 | 53.1 | 66.9 | 63.7 | 56.5 |
| Any chemotherapy, % | 42.6 | 40.2 | 76.1 | 62.8 | 69.6 | 49.7 | 54.3 |
| Chemotherapy after diagnostic splenectomy, % c | 14.9 | 32.9 | 70.7 | 51.3 | 58.3 | 33.7 | 44.1 |
Percentages may not sum up to 100.0% due to rounding.
a
Recorded in the data base as the first course of therapy for the lymphoma.
b
As a proportion of all splenectomies that were diagnostic (i.e. with 0 days between surgery and diagnosis)
c
Proportion of patients who received chemotherapy after undergoing a diagnostic splenectomy.
DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; MCL: mantle cell lymphoma; SMZL: splenic marginal zone lymphoma.